Certara Highlights Strategic Resilience at Jefferies London Healthcare Conference

At the 2025 Jefferies London Healthcare Conference, Certara, Inc. (NASDAQ: CERT) took the stage to address recent headwinds and outline its future-focused strategy. CEO William Feehery acknowledged a third‑quarter slowdown in bookings—especially among Tier‑1 clients and within its regulatory‑services arm—citing volatility in that segment and broader macro uncertainty. In response, Certara is doubling down on its growth engines: biosimulation, platform integration, and artificial‑intelligence‑driven deployment. The firm has introduced new software products—including Simcyp Discovery and Simcyp Biopharmaceuticals—designed to broaden access to its modeling capabilities across pre‑clinical and formulation sciences. Its newly launched platform, Certara IQ, aims to industrialize quantitative systems pharmacology (QSP) modelling, bridging services and software. On the regulatory‑services front, Certara has placed the business under strategic review, with the expectation of clarity by year‑end. The company cited disruptions at the Food and Drug Administration (FDA) as a contributing factor to recent booking softness, but emphasized this is not seen as core to its long‑term strategy. Looking ahead to 2026, Certara anticipates revenue acceleration driven by increasing software penetration, growing biosimulation usage, and regulatory progress on non‑animal testing pathways. With a healthy backlog providing near‑term stability, the company remains confident that current headwinds are cyclical rather than structural. #drugdevelopment #biosimulation #pharmatech #Certara #SlimScan #GrowthStocks #CANSLIM